Future research must focus on multiplexed editing using CRISPR/Cas9 to simultaneously manipulate several signaling pathways, including IL-12 secretion and CCR7 migratory receptor expression, to induce a robust immune response against the tumor. The gene discussed is CCR7; the disease is neoplasm.